Lack Of Funding Has “Hobbled” FDA Postmarketing Drug Safety Work – IoM
This article was originally published in The Tan Sheet
Executive Summary
Congress must approve "substantially increased" funding resources to improve FDA's drug safety system and implement much needed widespread change, according to a final report from the Institute of Medicine